Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 490 results for %s

  1. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    magnitude. It is recommended that data are collected using validated measure(s) of HRQoL, including EQ-5D. Source guidance details Comes...

    Research recommendation
    Published
    26 October 2020

  2. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

    Medtech innovation briefing
    Published
    30 July 2018

  3. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    magnitude. It is recommended that data are collected using validated measure(s) of HRQoL,including EQ-5D. Source guidance details Comes...

    Research recommendation
    Published
    9 June 2015

  4. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

    Medtech innovation briefing
    Published
    17 December 2019

  5. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)

    We have moved Medical technologies guidance 65 to become HealthTech guidance 607. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

    Medtech innovation briefing
    Published
    9 February 2017

  7. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA698

  8. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA336

  9. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    27 September 2019
    View recommendations

    Sections for NG141

  10. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

    Medtech innovation briefing
    Published
    8 April 2020

  11. PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)

    NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .

    Medtech innovation briefing
    Published
    9 December 2019

  12. eXroid for internal haemorrhoids (MIB201)

    NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .

    Medtech innovation briefing
    Published
    10 December 2019

  13. Key question: effective

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  14. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA373

  15. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

    Medtech innovation briefing
    Published
    4 March 2019